NCT06789562 is a clinical trial of F-18FDG PET/CT and CT in Lung Cancer, sponsored by Assiut University.

Who is sponsoring NCT06789562?

NCT06789562 is sponsored by Assiut University.

What drugs are being tested in NCT06789562?

Interventions in NCT06789562: F-18FDG PET/CT and CT.

What condition does NCT06789562 study?

NCT06789562 studies Lung Cancer.

Is NCT06789562 still recruiting?

NCT06789562 is currently not yet recruiting. Last updated 23 January 2025.

Last reviewed 2025-01-23 · How we verify

NCT06789562

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer

Not yet recruiting Last updated 23 January 2025

What this trial tests

trial testing F-18FDG PET/CT and CT in Lung Cancer in 54 participants. Not yet recruiting.

Timeline

30 January 2025

Primary endpoint
30 November 2027

31 December 2027

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	54
Start date	30 January 2025
Primary completion	30 November 2027
Estimated completion	31 December 2027

Drugs / interventions tested

F-18FDG PET/CT and CT

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Assiut University

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Is to compare F-18 FDG PET/CT to routine CT in staging of non-small lung cancer and effect on change management.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06789562 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 23 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing